1·The results of two randomized trials looking at the combination of bevacizumab and cetuximab are awaited.
两项对联合应用贝伐单抗和西妥昔单抗的随机试验结果还须等待。
2·But these drugs called EGFR inhibitors, such as cetuximab, have not been very effective against colon cancer.
但这些称为EGFR抑制因子如西妥昔单抗的药物对结肠癌的治疗还不是很有效。
3·Methods We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab.
方法：我们随机分组表皮生长因子受体阳性、转移性、不可切除结直肠癌患者接受FOLFIRI单独化疗或联合西妥昔单抗化疗。
4·Because ERBB2 isn't affected by cetuximab, this is an easy way for cancers to become resistant to the drug.
由于ERBB2不受西妥昔单抗的影响，这是一种使癌症对药物产生耐药性的简单方法。
5·The pharmacologic actions of cetuximab and its clinical evaluation are reviewed in this paper.
本文综述了西妥昔单抗的药理作用及临床评价。